drugset / Trial / NCT00118040

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

NCT00118040

Phase 2 Completed 60 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindTreatment

Summary

Studying samples of blood, urine, and tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors learn how genistein or placebo works in patients with bladder cancer. This randomized phase II trial is studying genistein or placebo to compare how they work in patients who are undergoing surgery for bladder cancer.

Timeline

Start
2005-06-24
Primary completion
2010-08-15
Completion
2010-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Genistein Other / unclassified 300 mg Oral
Subject Genistein Other / unclassified 600 mg Oral